The
International
Cancer
of
the
Pancreas
Screening
Consortium
met
in
2018
to
update
its
consensus
recommendations
for
management
individuals
with
increased
risk
pancreatic
cancer
based
on
family
history
or
germline
mutation
status
(high-risk
individuals).A
modified
Delphi
approach
was
employed
reach
among
a
multidisciplinary
group
experts
who
voted
statements.
Consensus
considered
reached
if
≥75%
agreed
disagreed.Consensus
55
main
goals
surveillance
(to
identify
high-grade
dysplastic
precursor
lesions
and
T1N0M0
cancer)
remained
unchanged.
Experts
that
those
familial
risk,
should
start
no
earlier
than
age
50
10
years
youngest
relative
cancer,
but
were
split
whether
at
55.
Germline
ATM
carriers
one
affected
first-degree
are
now
eligible
surveillance.
preferred
tests
endoscopic
ultrasound
MRI/magnetic
retrograde
cholangiopancreatography,
how
alternate
these
modalities.
Annual
is
recommended
absence
concerning
lesions.
Main
areas
disagreement
included
be
performed
hereditary
pancreatitis,
indeterminate
lesions.Pancreatic
selected
high-risk
detect
early
precursors,
research
setting
by
teams
centres
appropriate
expertise.
Until
more
evidence
supporting
available,
benefits,
risks
costs
need
additional
evaluation.
A
real-time
trial
of
a
cancer
blood
test
Cancers
diagnosed
early
are
often
more
responsive
to
treatment.
Blood
tests
that
detect
molecular
markers
have
successfully
identified
individuals
already
known
the
disease.
Lennon
et
al.
conducted
an
exploratory
study
closely
reflects
way
in
which
such
would
be
used
future.
They
evaluated
feasibility
and
safety
incorporating
multicancer
into
routine
clinical
care
10,000
women
with
no
history
cancer.
Over
12-month
period,
detected
26
cancers
different
types.
combination
positron
emission
tomography–computed
tomography
(PET-CT)
imaging
led
surgical
removal
nine
these
cancers.
Use
did
not
result
large
number
futile
follow-up
procedures.
Science
,
this
issue
p.
eabb9601
The
International
Cancer
of
the
Pancreas
Screening
Consortium
met
in
2018
to
update
its
consensus
recommendations
for
management
individuals
with
increased
risk
pancreatic
cancer
based
on
family
history
or
germline
mutation
status
(high-risk
individuals).A
modified
Delphi
approach
was
employed
reach
among
a
multidisciplinary
group
experts
who
voted
statements.
Consensus
considered
reached
if
≥75%
agreed
disagreed.Consensus
55
main
goals
surveillance
(to
identify
high-grade
dysplastic
precursor
lesions
and
T1N0M0
cancer)
remained
unchanged.
Experts
that
those
familial
risk,
should
start
no
earlier
than
age
50
10
years
youngest
relative
cancer,
but
were
split
whether
at
55.
Germline
ATM
carriers
one
affected
first-degree
are
now
eligible
surveillance.
preferred
tests
endoscopic
ultrasound
MRI/magnetic
retrograde
cholangiopancreatography,
how
alternate
these
modalities.
Annual
is
recommended
absence
concerning
lesions.
Main
areas
disagreement
included
be
performed
hereditary
pancreatitis,
indeterminate
lesions.Pancreatic
selected
high-risk
detect
early
precursors,
research
setting
by
teams
centres
appropriate
expertise.
Until
more
evidence
supporting
available,
benefits,
risks
costs
need
additional
evaluation.
